Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 7/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.44 |
| ▸ | MAPT | P10636 | 4/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
| ▸ | ATM | Q13315 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.39 |
| ▸ | GLA | P06280 | 1/20 | 0.39 |
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.39 |
| ▸ | BLM | P54132 | 1/20 | 0.39 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | PABPC1 | P11940 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4185735 | 0.85 | ALDH1A1 (0.52) | L3MBTL1ALDH1A1MAPTPOLBNPSR1 | |
| SCHEMBL1547751 | 0.79 | L3MBTL1 (0.54) | L3MBTL1ALDH1A1MAPTRAB9AATM | |
| SCHEMBL198741 | 0.79 | L3MBTL1 (0.62) | L3MBTL1ALDH1A1MAPTRAB9AATM | |
| SCHEMBL31122982 | 0.79 | L3MBTL1 (0.62) | L3MBTL1ALDH1A1MAPTRAB9AATM | |
| SCHEMBL10979658 | 0.78 | SMN1; SMN2 (0.45) | L3MBTL1ALDH1A1MAPTHPGDNPSR1 | |
| SCHEMBL2525928 | 0.78 | L3MBTL1 (0.62) | L3MBTL1ALDH1A1MAPTRAB9AATM | |
| SCHEMBL8082754 | 0.78 | L3MBTL1 (0.53) | L3MBTL1ALDH1A1MAPTRAB9AATM | |
| SCHEMBL687479 | 0.77 | CA1 (0.46) | L3MBTL1ALDH1A1MAPTRAB9AHPGD | |
| SCHEMBL3785688 | 0.76 | ALDH1A1 (0.52) | L3MBTL1ALDH1A1MAPTRAB9AATM | |
| SCHEMBL2883927 | 0.76 | L3MBTL1 (0.51) | L3MBTL1ALDH1A1MAPTRAB9AATM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1203766-B1 | Carboxylic acid derivatives that inhibit the binding of integrins to their receptors | ENCYSIVE PHARMACEUTICALS INC (US) | 2012-02-29 | — | — | EP | disclosed |
| CN-101475526-B | Carboxylic acid derivatives inhibiting the binding of integrins to receptors thereof | TEXAS BIOTECHNOLOGY CORP | 2011-05-25 | — | — | CN | disclosed |
| US-7812038-B2 | Carboxylic acid derivatives that inhibit the binding of integrins to their receptors | ENCYSIVE PHARMACEUTICALS, INC. (US) | 2010-10-12 | — | — | US | disclosed |
| CN-101475526-A | Carboxylic acid derivatives inhibiting the binding of integrins to receptors thereof | TEXAS BIOTECHNOLOGY CORP (US) | 2009-07-08 | — | — | CN | disclosed |
| EP-1567505-A4 | COMBINATION PRODUCTS WITH CARBOXYLIC ACID DERIVATIVES THAT INHIBIT THE BINDING OF INTEGRINS TO THEIR RECEPTORS AND OTHER THERAPEUTIC COMPOUNDS | SCHERING CORP (US) | 2009-07-01 | — | — | EP | disclosed |
| CN-100491353-C | Carboxylic acid derivatives inhibiting the binding of integrins to their receptors | TEXAS BIOTECHNOLOGIES CORP (US) | 2009-05-27 | — | — | CN | disclosed |
| US-20070060608-A1 | Combination products with carboxylic acid derivatives that inhibit the binding of integrins to their receptors and other therapeutic compounds | ENCYSIVE PHARMACEUTICALS INC. (US) | 2007-03-15 | — | — | US | disclosed |
| US-20060276476-A1 | Carboxylic acid derivatives that inhibit the binding of integrins to their receptors | BIEDIGER RONALD J | 2006-12-07 | — | — | US | disclosed |
| CN-1735601-A | Combination products with carboxylic acid derivatives that inhibit the binding of integrins to their receptors and other therapeutic compounds | SCHERING CORP (US) | 2006-02-15 | — | — | CN | disclosed |
| US-6972296-B2 | Carboxylic acid derivatives that inhibit the binding of integrins to their receptors | ENCYSIVE PHARMACEUTICALS INC. (US) | 2005-12-06 | — | — | US | disclosed |
| EP-1567505-A2 | COMBINATION PRODUCTS WITH CARBOXYLIC ACID DERIVATIVES THAT INHIBIT THE BINDING OF INTEGRINS TO THEIR RECEPTORS AND OTHER THERAPEUTIC COMPOUNDS | ENCYSIVE PHARMACEUTICALS INC. (US) | 2005-08-31 | — | — | EP | disclosed |
| WO-2004044046-A2 | COMBINATION PRODUCTS WITH CARBOXYLIC ACID DERIVATIVES THAT INHIBIT THE BINDING OF INTEGRINS TO THEIR RECEPTORS AND OTHER THERAPEUTIC COMPOUNDS | ENCYSIVE PHARMACEUTICALS (US) | 2004-05-27 | — | — | WO | disclosed |
| US-6723711-B2 | VASCULAR CELL ADHESION MOLECULES AND FIBRONECTINS; ASTHMA, MULTIPLE SCLEROSIS, ARTHRITIS, INFLAMMATORY BOWEL DISEASE, CONTACT HYPERSENSITIVITY, CARDIAC ALLOGRAFT REJECTION AND DIABETES TREATMENT | TEXAS BIOTECHNOLOGY CORPORATION | 2004-04-20 | — | — | US | disclosed |
| US-20040063955-A1 | Carboxylic acid derivatives that inhibit the binding of integrins to their receptors | ENCYSIVE PHARMACEUTICALS INC. | 2004-04-01 | — | — | US | disclosed |
| US-20030199692-A1 | Propanoic acid derivatives that inhibit the binding of integrins to their receptors | ENCYSIVE PHARMACEUTICALS INC. | 2003-10-23 | — | — | US | disclosed |
| CN-1412181-A | Carboxylic acid derivatives inhibiting the binding of integrins to their receptors | TEXAS BIOTECHNOLOGIES CORP (US) | 2003-04-23 | — | — | CN | disclosed |
| EP-1213288-A1 | Propanoic acid derivatives that inhibit the binding of integrins to their receptors | TEXAS BIOTECHNOLOGY CORPORATION (US) | 2002-06-12 | — | — | EP | disclosed |
| EP-1203766-A2 | Carboxylic acid derivatives that inhibit the binding of integrins to their receptors | TEXAS BIOTECHNOLOGY CORPORATION (US) | 2002-05-08 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060276476-A1 | Carboxylic acid derivatives that inhibit the binding of integrins to their receptors | VCAM1, ICAM1, ITGA1 | L3MBTL1 3947/4885ALDH1A1 53/4885MAPT 2314/4885 |
| US-20040063955-A1 | Carboxylic acid derivatives that inhibit the binding of integrins to their receptors | VCAM1, ICAM1, FN1 | L3MBTL1 4021/4885ALDH1A1 57/4885MAPT 2566/4885 |
| US-20070060608-A1 | Combination products with carboxylic acid derivatives that inhibit the binding of integrins to their receptors and other therapeutic compounds | VCAM1, ITGB1, ICAM1 | L3MBTL1 4418/4885ALDH1A1 92/4885MAPT 2591/4885 |
| US-20030199692-A1 | Propanoic acid derivatives that inhibit the binding of integrins to their receptors | VCAM1, ICAM1, FN1 | L3MBTL1 3461/4885ALDH1A1 59/4885MAPT 3022/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.